-
1 Comment
Apellis Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 45.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.9.
Apellis Pharmaceuticals, Inc's total revenue rose by inf% to $250M since the same quarter in the previous year.
Its net income has increased by 169.1% to $78M since the same quarter in the previous year.
Finally, its free cash flow grew by 271.8% to $141M since the same quarter in the previous year.
Based on the above factors, Apellis Pharmaceuticals, Inc gets an overall score of 5/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US03753U1060 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | 0.84 |
|---|---|
| Market Cap | 2B |
| Target Price | 42.2 |
| PE Ratio | None |
| Dividend Yield | None |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for APLS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
